Emotion and Motivation in Patients With Psychosis

Schizophrenia Clinical Trial

Official title:

Influence of Emotion and Motivation on Behaviour and Neural Activity in Patients With Psychosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02853019
• Other study ID #: 6152
• Status: Recruiting
• Phase: N/A
• Start date: February 2, 2017
• Est. completion date: June 2025

Study information

• Verified date: August 2023
• Source: University Hospital, Strasbourg, France
• Contact: Anne GIERSCH
• Phone: 03 88 11 64 71
• Email: giersch[@]unistra.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Anhedonia and avolition reflect emotional and motivational disorders, respectively. However, if these disorders play a major role in the symptomatology of schizophrenia, their mechanisms remain poorly understood, and existing treatments are inefficient on these symptoms. The literature suggests that the impairment does not concern emotion or motivation per se, but rather their influence on cognition. This project aims at using recent advances in the fundamental domain to better understand the cognitive and neuronal mechanisms of the patients' alterations, and especially how emotion and motivation influence cognition in schizophrenia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: June 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• diagnostic and Statistical Manual of Mental Disorders criteria for schizophrenia

Exclusion Criteria:

• addiction problem
• invalidating visual sensory problems
• neurological history
• for the healthy volunteers: psychiatric history

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Other:
• Electroencephalogram
electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli

Behavioral:
• Cognitive tasks
- clinical scales and subjective assessments of emotional and motivational stimuli
• subjective evaluation scales
- clinical scales and subjective assessments of emotional and motivational stimuli

Locations

Country	Name	City	State
France	Unité INSERM 1114	Strasbourg

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France	Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the amplitude of the CNV (Contingent Negative Variation) as a function of the primer displayed on the screen	Before each cognitive trial a primer will be displayed, which will be either neutral or convey emotion or motivation. The investigators will check whether this primer affects the subjects preparation by measuring the CNV, which is an evoked potential recorded with electroencephalography, and indexing preparatory effort.	During EEG sessions, at experimental session 1 (Day 0) and experimental session 2 (up to Day 120)
Secondary	Change in the amplitude of the LPP (Late Positive Potential) as a function of the primer displayed on the screen	The investigators will check whether primers affect the subjects attention by measuring the LPP, which is an evoked potential recorded with electroencephalography, and indexing sustained attention.	During EEG sessions, at experimental session 1 (Day 0) and experimental session 2 (up to Day 120)